VISHEE(SH:688580)2024-04-25 09:20Financial Performance - The total revenue for Q1 2024 was CNY 87,670,336.46, representing a decrease of 8.24% compared to the same period last year[5] - The net profit attributable to shareholders was CNY 21,753,153.33, down 27.69% year-over-year[5] - The net profit after deducting non-recurring gains and losses was CNY 19,210,945.69, a decline of 27.42% compared to the previous year[5] - Basic earnings per share were CNY 0.3196, reflecting a decrease of 27.45% year-over-year[6] - Total operating revenue for Q1 2024 was ¥87,670,336.46, a decrease of 8.8% compared to ¥95,539,491.61 in Q1 2023[20] - Net profit for Q1 2024 was ¥21,753,153.33, down 27.8% from ¥30,081,694.57 in Q1 2023[22] - Earnings per share (EPS) for Q1 2024 was ¥0.3196, compared to ¥0.4406 in Q1 2023, reflecting a decline of 27.4%[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,796,524,431.04, a decrease of 0.53% from the end of the previous year[6] - As of March 31, 2024, the total assets of Nanjing Weisi Medical Technology Co., Ltd. amounted to CNY 1,796,524,431.04, a slight decrease from CNY 1,806,024,041.14 at the end of 2023[17] - The company reported a total liability of ¥147,660,023.33 as of Q1 2024, down from ¥179,268,822.19 in the previous year[21] - Total current liabilities decreased to CNY 116,027,773.52 from CNY 151,683,003.46, a reduction of about 23.5%[18] - The non-current assets totaled CNY 574,292,376.34, up from CNY 551,196,031.71, marking an increase of about 4.5%[18] Cash Flow - Cash flow from operating activities for Q1 2024 was ¥9,386,067.11, down from ¥11,154,972.16 in Q1 2023[24] - Cash inflow from investment activities in Q1 2024 was ¥275,133,776.46, compared to ¥658,739,670.98 in Q1 2023, indicating a significant decrease[24] - The net cash flow from investing activities was -$44,169,962.17, compared to -$14,853,732.18 in the previous year, indicating a significant increase in cash outflow for investments[25] - The total cash and cash equivalents at the end of the period was $1,112,314,830.54, down from $1,238,814,450.73 in the previous year, reflecting a decrease of approximately 10.2%[25] - The cash outflow from financing activities was $6,702,302.11, compared to $5,159,439.43 in the previous year, showing an increase of about 29.9%[25] - The initial cash and cash equivalents balance was $1,153,801,027.71, compared to $1,247,672,650.18 in the previous year, indicating a decrease of approximately 7.5%[25] Research and Development - Research and development expenses totaled CNY 18,851,562.73, which is 21.5% of total revenue, an increase of 5.57 percentage points year-over-year[6] - Research and development expenses rose to ¥15,427,799.83 in Q1 2024, up from ¥11,739,724.55 in Q1 2023, marking an increase of 31.5%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,278[12] - The largest shareholder, Wang Zhiyu, holds 39.29% of the shares, totaling 26,961,547 shares[12] Company Activities - The company has not reported any new product launches or technological advancements during this quarter[15] - There are no significant mergers or acquisitions reported in the current quarter[15] - The company has not provided specific future guidance or market expansion strategies in this report[15] - The company has not adopted new accounting standards or interpretations for the current year, which may impact future financial reporting[25] - The company’s cash flow management strategies may need to be reassessed given the increased cash outflows and reduced cash balances[25]